title: Vinblastine in the treatment of children and adolescents with refractory immune thrombocytopenia.
authors.affiliation: Pediatric Hematology Unit, Armand-Trousseau University Hospital, Paris, France. brice.fresneau@etu.upmc.fr
authors.forename: Brice
authors.initials: B
authors.lastname: Fresneau
authors.forename: Arnaud
authors.initials: A
authors.lastname: Petit
authors.forename: Mary-France
authors.initials: MF
authors.lastname: Courcoux
authors.forename: Marie-Dominique
authors.initials: MD
authors.lastname: Tabone
authors.forename: Anne
authors.initials: A
authors.lastname: Auvrignon
authors.forename: Judith
authors.initials: J
authors.lastname: Landman-Parker
authors.forename: Guy
authors.initials: G
authors.lastname: Leverger
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D004351:Drug Resistance; D006470:Hemorrhage / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007223:Infant; D008297:Male; D008499:Medical Records; D009437:Neuralgia / Q000139:chemically induced; D010976:Platelet Count; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology / Q000517:prevention & control; D012074:Remission Induction; D012189:Retrospective Studies; D055502:Secondary Prevention; D050257:Tubulin Modulators / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D007166:Immunosuppressive Agents; D050257:Tubulin Modulators; D014747:Vinblastine